Real-World Data Confirm That the Integration of Deuterium Depletion into Conventional Cancer Therapy Multiplies the Survival Probability of Patients

Over thirty years of basic research has demonstrated that the deuterium-to-hydrogen ratio plays a pivotal role in regulating metabolism and cell growth; via a sub-molecular regulatory system that orchestrates the intricate complexity of life in eukaryotic organisms. Deuterium depletion, achieved through deuterium-depleted water (DDW), has shown anticancer effects in vitro, in vivo, and in phase 2 prospective and retrospective clinical studies.METHODS: In this population-based observational study, 2,649 cancer patients undergoing conventional therapy and consuming DDW were included between October 1992 and October 2024. With various cancer types and stages and conventional therapies received, they are representing a broad spectrum of the Hungarian cancer population. Survival was selected as the primary endpoint, and median survival time (MST) of these patients and various subgroups was calculated and compared to the overall Hungarian cancer population's MST of 2.4 years.RESULTS: For the entire study population, MST from diagnosis was 12.4 years (95% CI: 9.8–14.9), and from the initiation of DDW treatment, 7.6 years (95% CI: 5.9–9.3). A statistically significant correlation was observed between the duration of DDW treatment and survival, both from the time of diagnosis (Pearson’s coefficient: r = 0.476, p <0.001) and from the start of DDW treatment (r = 0.635, p <0.001). The analysis also showed that the duration of DDW consumption and the time gap from the diagnosis crucially influence the outcome. Excluding patients who died within 120 days of initiating DDW treatment, those who consumed DDW for less than 120 days, and those who began DDW treatment later than 9 months of diagnosis (1,243 patients), the MST from the start of DDW consumption increased from 7.6 years to 11.6 years (95% CI: 8.9–14.2).CONCLUSION: Utilizing DDW enables targeted intervention in the sub-molecular regulatory system, paving the way for innovative therapeutic applications and a more profound understanding of cellular processes. Integrating deuterium depletion into conventional cancer therapies has the potential to significantly enhance survival rates and reduce cancer-related mortality by 75–80%.